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Background-—Adults with a systemic right ventricle (sRV) have a high risk of cardiac complications. This study aimed to identify
prognostic markers in adults with sRV based on clinical evaluation, echocardiography, and blood biomarkers.
Methods and Results-—In this prospective cohort study, consecutive clinically stable adults with sRV caused by Mustard- or
congenitally corrected transposition of the great arteries were included (2011–2013). Eighty-six patients were included (age
379 years, 65% male, 83% New York Heart Association functional class I, 76% Mustard transposition of the great arteries, 24%
congenitally corrected transposition of the great arteries). Venous blood sampling was performed including N-terminal
pro B-type natriuretic peptide, high-sensitive-troponin-T, high-sensitivity C-reactive protein, growth differentiation factor-15,
galectin-3, red cell distribution width, estimated glomerular ﬁltration rate, and hemoglobin. Besides conventional echocardiographic
measurements, longitudinal, circumferential, and radial strain were assessed using strain analysis. During a median follow-up of 5.9
(interquartile range 5.3–6.3) years, 19 (22%) patients died or had heart failure (primary end point) and 29 (34%) patients died or had
arrhythmia (secondary end point). Univariable Cox regression analysis was performed using dichotomous or standardized continuous
variables. New York Heart Association functional class >I, systolic blood pressure, and most blood biomarkers were associated with
the primary and secondary end point (galectin-3 not for primary, N-terminal pro B-type natriuretic peptide and high-sensitivity C-
reactive protein not for secondary end point). Growth differentiation factor-15 showed the strongest association with both end points
(hazard ratios; 2.44 [95% CI 1.67–3.57, P<0.001], 2.00 [95% CI 1.46–2.73, P<0.001], respectively). End-diastolic basal dimension of
the subpulmonary ventricle was associated with both end points (hazard ratio: 1.95 [95% CI 1.34–2.85], P<0.001, 1.70 [95% CI 1.21–
2.38, P=0.002], respectively). Concerning strain analysis, only sRV septal strain was associated with the secondary end point (hazard
ratio 0.58 [95% CI 0.39–0.86], P=0.006).
Conclusions-—Clinical, conventional echocardiographic, and blood measurements are important markers for risk stratiﬁcation in
adults with a sRV. The value of novel echocardiographic strain analysis seems limited. ( J Am Heart Assoc. 2019;8:e013745. DOI:
10.1161/JAHA.119.013745.)
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T ransposition of the great arteries (TGA) is a complexcongenital heart defect, with an incidence of 0.31 per
1000 live births per year.1 Before the arterial switch
operation was introduced, TGA patients were operated on
according to the Mustard or Senning procedure (M-TGA).
During this procedure, a bafﬂe is created at the levels of
the atria (atrial switch operation) resulting in a right
ventricle supporting the systemic circulation (sRV).2
Congenitally corrected TGA (ccTGA) is the name given to
a morphologic situation where there is both atrioventricu-
lar and ventriculoarterial discordance, also resulting in a
sRV.3
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Since the right ventricle is designed for volume load and
not pressure overload,4 the right ventricle will degenerate
earlier, leading to an impaired ventricular function over time.
Dysfunction of the sRV may subsequently lead to cardiac
complications such as heart failure (HF), arrhythmias, and
death.5–8 Currently, it is not clear which patients are at higher
risk of developing complications, nor is it clear how we can
best monitor them over time. Identiﬁcation of high-risk
patients is important to enable clinicians to intervene at the
right time and also to establish a better expectation of
management for patients. However, at the moment prospec-
tive longitudinal studies investigating prognostic factors in
patients with a sRV are scarce. Studies have investigated
prognosis in adult congenital heart disease,6 but rarely in a
prospective manner pertaining exclusively to sRV patients.9
Therefore, this study aimed to identify the prognostic value
of clinical variables, echocardiographic- and blood biomarkers
in adult patients with a sRV.
Methods
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
Study Population and Design
Patients with M-TGA and ccTGA were extracted from a
prospective cohort of consecutive, clinically stable adults
with congenital heart disease who were included during a
routine visit to the outpatient clinic of the Erasmus Medical
Center, Rotterdam between April 2011 and April 2013.
Exclusion criteria were the following: age <18 years, preg-
nancy, renal dysfunction (creatinine level >200 lmol/L), or
patients not capable of understanding and signing informed
consent. In our center, the Senning procedure in patients
with TGA had not been performed; therefore, only M-TGA
patients were included in this study.
All patients underwent clinical examination by a cardiol-
ogist, 12-lead electrocardiography, echocardiography, and
venous blood sampling. The study protocol has been
described in more detail previously.10 This study was
carried out according to the principles of the Declaration
of Helsinki and approved by the local ethics committee.
Written informed consent was obtained from all participants.
Echocardiography and Speckle-Tracking Analysis
Two-dimensional grayscale harmonic images were obtained
with patients in the left lateral decubitus position using a
commercially available iE33 or Epic C7 ultrasound system
(Philips Medical Systems, Best, The Netherlands) equipped
with a transthoracic broadband S5-1 (1–5 MHz) or X5-1
matrix transducer (composed of 3040 elements, with 1 to
5 MHz extended operating frequency range).
Echocardiographic assessment was performed according
to the European Society of Cardiology (ESC) and American
Society of Echocardiography (ASE) guidelines for echocardio-
graphic chamber quantiﬁcation.11,12
Speckle tracking analysis was performed (RWG) using
TomTec (TomTec 2D CPA using dedicated RV software;
TomTec Imaging Systems, Unterschleissheim, Germany) fol-
lowing the current consensus document on strain analysis.13
Longitudinal strain in the apical 4- chamber view was
assessed for all patients, and circumferential and radial strain
were only assessed in the short-axis view in M-TGA patients
as the appropriate view required for analysis is unobtainable
in the ccTGA patients because of the orientation of the sRV in
the thorax. Similarly, subpulmonary left ventricular diameters
were not measured in the ccTGA group.
Laboratory Results
Peripheral venous blood sampling was performed at the day of
study inclusion and was for research purposes only. Blood
samples were then transferred to the clinical chemistry
laboratory of our center within 2 hours after withdrawal. N-
terminal pro B-type natriuretic peptide (NT-proBNP), red cell
distribution width (RDW), and estimated glomerular ﬁltration
rate were directly determined in fresh blood samples, whereas
the rest of the samples were aliquoted and stored at 80°C.
Serum levels of growth differentiation factor-15 (GDF-15),
high-sensitive C-reactive protein, galectin-3, and high-sensitive
troponin T (hs-TnT) were determined in batches. Samples were
exposed to only 1 freeze–thaw cycle. The laboratory analyses of
Clinical Perspective
What Is New?
• In adults with a systemic right ventricle, blood biomarkers
carry signiﬁcant prognostic value, of which growth differen-
tiation factor-15 is the strongest prognosticator of all blood
biomarkers, and not the conventional biomarker N-terminal
pro-brain natriuretic peptide.
• Echocardiographic strain analysis is of limited prognostic
value in adults with a systemic right ventricle, while
subpulmonary end-diastolic dimension and tricuspid regur-
gitation are predictive of outcomes.
What Are the Clinical Implications?
• Given the complexity of the failing systemic right ventricle,
risk stratiﬁcation should consist of clinical variables, blood-
and echocardiographic markers, and implementation of
blood biomarkers should be especially encouraged.
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all biomarkers have been described in more detail previ-
ously.10,14–17
Deﬁnition of Events
Given the relatively low mortality rate in this population, we
chose to take combined end points. The primary end point
was composed of all-cause mortality or HF. HF was deﬁned as
signs and symptoms of HF requiring hospital admission, or
requiring initiation or change in HF medication. The secondary
end point was a composite of all-cause mortality or arrhyth-
mia. We deﬁned arrhythmia as any symptomatic and regis-
tered arrhythmia, or arrhythmias requiring treatment.
Presence of premature ventricular complexes or premature
atrial complexes were not regarded as arrhythmias. HF and
arrhythmias were treated as separate end points because of
potential event-speciﬁc predictors because of a probable
different mechanism of clinical worsening. Follow-up was
assured by yearly scheduled visits to the adult congenital
heart disease outpatient clinic during the ﬁrst 4 years of
follow-up, and end points were systematically tracked by 2
investigators (LG and JR) until January 1, 2018. Survival status
was checked in the Municipal Population Register.
Statistical Analysis
Continuous variables with a normal distribution were pre-
sented as mean SD, otherwise the median and interquartile
range was presented. For blood biomarkers, the geometric
mean was given in addition to the median. Patients were
stratiﬁed according to diagnosis (M-TGA or ccTGA). Contin-
uous variables between these groups were compared using
the unpaired t test or Mann–Whitney U test as appropriate.
For frequencies, Fisher exact test was performed.
Missing data were addressed by multiple imputation before
any further statistical analyses were performed. Multiple
imputation was performed in SPSS using 5 imputations and
based on all relevant patient characteristics, including the end
points. End points were not imputed. Biomarker levels were
log-transformed to correct for a skewed distribution before
further analysis.
Correlations between blood biomarkers and echocardio-
graphic measurements were reﬂected by Spearman correlation
coefﬁcient. The Kaplan–Meier estimator was used to obtain
survival curves stratiﬁed according to the diagnosis groups.
Survival functions were compared using the log-rank test.
Cox regression analysis was performed based on the entire
study population. All continuous echocardiographic and blood
biomarkers variables were transformed into z scores to obtain
standardized hazard ratios for the associations with the end
points. Tricuspid regurgitation was treated as continuous
variable (0–3), but not standardized. Univariable Cox
regression was performed to assess associations between
variables and end points. Additionally, all univariable associ-
ations were alternately adjusted for New York Heart Associ-
ation (NYHA) functional class (NYHA I versus NYHA II/III) in
multivariable analyses. Comparisons of strength of associa-
tions were made on the basis of standardized hazard ratios.
As post hoc analysis, a subgroup analysis was performed that
was restricted to M-TGA patients only.
A 2-sided P value of <0.05 was considered statistically
signiﬁcant. Statistical tests were performed using SPSS
Statistics, version 24.0.
Results
Baseline Characteristics
In this prospective cohort study, 86 patients were included: 65
patients with M-TGA and 21 patients with ccTGA. The patient
selection process is shown in Figure S1. Overall, the mean age
was 379 years, 56 (65%) were men, and most patients were
in NYHA class I (83%) (Table 1). Anticoagulants were more
often prescribed in ccTGA patients than in M-TGA patients.
M-TGA patients were more often in sinus rhythm than ccTGA
patients and had an implantable cardioverter deﬁbrillator less
often. In patients with ccTGA, signiﬁcantly higher levels of
RDW and hs-TnT were found, compared with M-TGA patients.
The sRV end-diastolic annulus was 50.45.9 mm in the
M-TGA group, which was larger compared with the ccTGA
group: 34.74.6 mm. Sixty patients (70%) had at least a
moderately impaired sRV. Speckle tracking analysis showed
that the mean longitudinal strain of the sRV free wall was
15.53.9% and the mean sRV circumferential strain was
12.03.8%.
Correlations Between Echocardiographic
Measurements and Blood Biomarkers
Both higher levels of NT-proBNP and hs-TnT were weakly
correlated with a larger subpulmonary end diastolic dimen-
sion. Weak correlations were also found between higher levels
of galectin-3 and lower sRV global longitudinal strain and
lower sRV longitudinal strain of the septal wall (Table 2).
Mutual blood biomarker correlations were present, though
no strong correlations were found. The strongest correlation
was found between NT-proBNP and hs-TnT (r=0.48, P<0.001)
(Table 2).
Follow-Up
Follow-up was complete in 99% of the patients. After a median
follow-up period of 5.9 (interquartile range 5.3–6.3) years, 19
patients (22%) reached the primary end point and 29 patients
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Table 1. Baseline Characteristics for All Patients With a sRV and Stratiﬁed According to Mustard-TGA and ccTGA Patients
Complete, n (%) All Patients (n=86) Mustard-TGA (n=65) ccTGA (n=21) P Value
Patient characteristics
Age, y 86 (100) 379 356 4114 0.06
Sex, man, n (%) 86 (100) 56 (65) 43 (66) 13 (62) 0.79
Age at initial repair, y 64 (98)  0.7 [0.4–2.2]  
Concomitant heart defect, n (%) 86 (100)
Ventricular septal defect 27 (31) 21 (32) 6 (29) 1.00
Pulmonary outflow tract obstruction 13 7 (11) 5 (24) 0.16
NHYA class ≥ II, n (%)* 86 (100) 15 (17) 12 (19) 3 (14) 1.00
Body mass index, kg/m2 84 (98) 24.84.0 25.04.3 24.22.8 0.41
Body surface area, m2 84 (98) 1.910.20 1.920.19 1.880.21 0.47
Systolic blood pressure, mm Hg 83 (97) 12514 12515 12413 0.87
Diastolic blood pressure, mm Hg 83 (97) 7912 7912 7810 0.64
Heart rate, beats/min 84 (98) 7213 7213 7111 0.86
Oxygen saturation >96%, n (%) 78 (91) 63 (81) 44 (76) 19 (95) 0.10
Cardiac medication use, n (%) 86 (100)
ACE-inhibitor 26 (30) 17 (26) 9 (43) 0.18
ARBs 5 (6) 2 (10) 3 (5) 0.59
b-blocker 19 (22) 11 (17) 8 (38) 0.07
Diuretics 17 (20) 11 (17) 6 (29) 0.34
Antiarrhythmic 13 (15) 10 (15) 3 (14) 0.90
Anticoagulants 20 (23) 11 (17) 9 (43) 0.034
Electrocardiography
QRS duration, ms 69 (80) 114 [105–130] 114 [105–127] 113 [105–137] 0.57
Rhythm, n (%) 86 (100) 0.006†
Sinus rhythm 59 (68) 50 (77) 9 (43)
Pacemaker rhythm 17 (20) 8 (12) 9 (43)
Atrial fibrillation 4 (5) 2 (3) 2 (9)
Other 6 (7) 5 (8) 1 (5)
Device implantation, n (%) 86 (100)
Pacemaker 17 (20) 13 (20) 4 (19) 1.00
ICD 9 (10) 4 (6) 5 (24) 0.036
Echocardiography
sRV dimensions
End-diastolic basal dimension, mm 57 (66) 59.68.4 58.98.2 61.19.0 0.35
End-diastolic annulus, mm 67 (78) 47.18.6 50.45.9 34.74.6 <0.001
End-systolic area, cm² 81 (95) 30.77.9 30.67.5 30.89.5 0.93
End-diastolic area, cm² 81 (95) 41.09.2 40.48.7 42.910.7 0.30
sRV systolic function
≥ Moderately impaired, n (%) 86 (100) 60 (70) 47 (72) 13 (62) 0.42
TAPSE, mm 45 (52) 13.03.0 12.93.1 13.62.3 0.64
RV fractional area change, n (%) 81 (95) 25.48.2 24.37.5 28.99.5 0.03
Continued
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(34%) reached the secondary end point. In 1 patient, an event
of HF overlapped with the presence of arrhythmia and
therefore reached both end points at the same time.
Considering all components of the end points separately (ie,
patients were not censored at the time of another end point
than the end point of interest), the occurrence of events were
5 deaths, 18 HF events, and 26 arrhythmias. Causes of death
were end-stage HF (n=2), cardiac arrest (n=1), sudden death,
presumed cardiac (n=1), and hemorrhagic shock (n=1). In 9
cases, HF required hospitalization; in the other cases HF
medication was initiated or changed. The nature of the
arrhythmias were 5 ventricular tachycardias and 21
Table 1. Continued
Complete, n (%) All Patients (n=86) Mustard-TGA (n=65) ccTGA (n=21) P Value
Tricuspid regurgitation, n (%) 86 (100) 0.038
None 12 (14) 6 (9) 6 (29)
Mild 46 (53) 40 (61) 6 (29)
Moderate 24 (28) 16 (25) 8 (38)
Severe 4 (5) 3 (5) 1 (4)
Strain parameters
LS of the RV free wall, % 77 (90) 15.53.9 15.03.2 16.75.5 0.21
LS of the RV septal wall, % 77 (90) 12.43.3 12.43.3 12.33.4 0.95
Global LS of sRV, % 77 (90) 13.83.4 13.63.1 14.24.1 0.50
Global CS of sRV, % 52 (80)  12.03.8  
Global RS of sRV, % 49 (75)  18.913.5  
Subpulmonary LV dimensions
LV end-diastolic diameter, mm/m² 51 (79)  224  
LV end-systolic diameter, mm/m² 49 (75)  154  
Subpulmonary LV function
≥ Moderately impaired, n (%) 86 (100) 2 (2) 2 (3) 0 
Laboratory‡
Hemoglobin, mmol Fe/L 81 (94) 9.5 [9.2–10.0]
9.4
9.5 [9.2–10.0]
9.4
9.3 [9.0–10.0]
9.4
0.96
RDW, % 81 (94) 13.1 [12.6–13.7]
13.2
13.0 [12.6–13.4]
13.1
13.5 [13.2–14.1]
13.5
0.027
eGFR, mL/min per 1.73 m2 84 (98) 90 [81–90]
85
90 [83–90]
85
89 [77–90]
83
0.16
NT-proBNP, pmol/L 85 (99) 30.9 [17.7–58.2]
34.5
27.4 [18.2–53.2]
32.7
44.3 [16.4–76.5]
41.1
0.36
Hs-troponin T, ng/L 85 (99) 6.0 [1.5–9.5]
2.4
5.0 [1.5–8.4]
4.6
8.9 [6.0–15.4]
9.1
0.004
GDF-15, ng/L 84 (98) 623 [501–886]
727
615 [498–862]
698
660 [519–1379]
830
0.29
Hs-CRP, mg/L 85 (99) 1.8 [0.8–3.5]
1.6
1.9 [0.7–3.6]
1.6
1.2 [0.8–2.7]
1.4
0.50
Galectin-3, ng/mL 85 (99) 12.7 [11.2–15.0]
12.7
12.7 [11.4–15.0]
12.7
12.8 [11.0–13.9]
13.0
0.99
ACE indicates angiotensin-converting enzyme; ARBs, angiotensin II receptor blocker; CC-TGA, congenitally corrected transposition of the great arteries; CRP, C-reactive protein; CS,
circumferential strain; eGFR, estimated glomerular ﬁltration rate; GDF-15, growth differentiation factor-15; Hs-CRP, high-sensitive C-reactive protein; ICD, implantable cardioverter
deﬁbrillator; LS, longitudinal strain; LV, left ventricular; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association; RDW, red cell distribution width; RS, radial
strain; sRV, systemic right ventricle; TAPSE, transannular plane systolic excursion.
*All patients were NYHA II except 1 patient who was NYHA class III.
†Compares sinus rhythm vs all other rhythms.
‡For the laboratory measurements, the geometric mean is shown on the second line in addition to the median and interquartile range.
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supraventricular tachycardias. Supraventricular tachycardias
included atrial ﬂutter (n=6), atrial ﬁbrillation (n=4), AV (nodal)
re-entry tachycardia (n=2), and other supraventricular tachy-
cardias (n=8). One patient had an AV-block.
Associations With End Points
Kaplan–Meier curves showed no signiﬁcant differences in the
risk of both end points among the M-TGA and ccTGA patients.
Cumulative HF-free survival at 6 years was 81% in ccTGA
patients versus 76% in M-TGA patients. Cumulative arrhythmia-
free survival was 67% versus 64%, respectively (Figure 1).
A lower systolic blood pressure, NYHA class >1, and loss of
sinus rhythm were signiﬁcantly associated with an increased
risk of the primary end point. All blood biomarkers showed a
signiﬁcant association with the primary end point, except
galectin-3. GDF-15 showed the strongest association with the
primary end point, and a relatively strong association was
found between high-sensitive C-reactive protein and RDW and
the primary end point (Figure 2). (Standard deviations of all
variables are presented in Table S1).
With regard to the secondary end point, systolic blood
pressure and NYHA functional class were again signiﬁcantly
associated with the end point. Notably, loss of sinus rhythm
was not associated with the risk of death or arrhythmias.
GDF-15, RDW, and galectin-3 showed the strongest associ-
ation of all biomarkers with the secondary end point. NT-
proBNP and high-sensitive C-reactive protein were the only
blood biomarkers not associated with the secondary end
point (Figure 3).
Regarding the echocardiographic variables (Figures 2 and
3), end-diastolic diameters of the sRV as well as subpul-
monary left ventricle were signiﬁcantly associated with both
end points. Tricuspid regurgitation was associated with the
primary but not the secondary end point. Of all strain
variables, only septal longitudinal strain showed a signiﬁcant
association with the secondary end point.
When adjusting associations between blood biomarkers
and the primary end point for NYHA class, only estimated
glomerular ﬁltration rate was no longer statistically signiﬁ-
cant. All clinical variables and sRV end diastolic dimension did
not remain associated with the primary end point, while
tricuspid regurgitation did show an independent association
with the primary end point. GDF-15, RDW, estimated
glomerular ﬁltration rate, systolic blood pressure, and heart
rate were independently associated with the secondary end
Table 2. Correlations Between Blood Biomarker and Echocardiographic (Strain) Measurements and Mutual Biomarker Correlations
HB RDW eGFR NT-proBNP Hs-TnT GDF-15 Hs-CRP Galectin-3
r r r r r r r r
Echocardiography
Tricuspid regurgitation 0.08 0.01 0.09 0.12 0.18 0.06 0.08 0.01
sRV end-diastolic annulus 0.07 0.11 0.13 0.04 0.06 0.05 0.06 0.21
sRV global LS§ 0.18 0.09 0.13 0.21 0.20 0.07 0.02 0.25*
sRV GCS§ 0.05 0.07 0.07 0.24 0.10 0.10 0.01 0.01
sRV LS freewall§ 0.16 0.03 0.21 0.19 0.17 0.03 0.03 .022
sRV LS septal wall§ 0.17 0.21 0.01 0.19 0.17 0.11 0.03 0.27*
LV EDDk 0.19 0.08 0.07 0.29* 0.35* 0.09 0.02 0.05
Blood biomarkers
RDW 0.09
eGFR 0.07 0.30†
NT-proBNP 0.19 0.34† 0.43‡
Hs-TnT 0.09 0.44‡ 0.33† 0.48‡
GDF-15 0.19 0.40† 0.43‡ 0.43‡ 0.32†
Hs-CRP 0.14 0.27* 0.22* 0.39‡ 0.21‡ 0.39‡
Galectin-3 0.04 0.31† 0.28† 0.20 0.26* 0.37† 0.31†
BSA indicates body surface area; CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate; GCS, global circumferential strain; GDF-15, growth differentiation factor-15; HB,
hemoglobin; Hs, high sensitive; LS, longitudinal strain; LV EDD, left ventricular end-diastolic dimension; NT-proBNP, N-terminal pro B-type natriuretic peptide; RDW, red cell distribution
width; sRV, systemic right ventricle; TnT, troponin T.
Level of signiﬁcance is indicated by the following symbols: *P<0.05, †P<0.01, ‡P<0.001.
§Variables were transformed to positive numbers for easier interpretation.
kIndexed for BSA.
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point as well as 2 echo markers: longitudinal strain of the sRV
septal wall and sRV global circumferential strain (Table S2).
Subgroup analysis restricted to M-TGA patients only
showed signiﬁcant associations with both end points for
age, systolic blood pressure, NYHA class, and loss of sinus
rhythm. Of all blood biomarkers, NT-proBNP yielded the
strongest association with the primary end point and GDF-15
was most strongly associated with the secondary end point.
Longitudinal strain of the free wall was signiﬁcantly associ-
ated with the secondary end point (Table S3).
Discussion
This prospective longitudinal cohort study consisting of 86
adults with a sRV showed that these patients are at high risk of
HF, arrhythmias, and death. This emphasizes the importance of
adequate risk stratiﬁcation. Higher NYHA class, lower systolic
blood pressure, and loss of sinus rhythm were signiﬁcantly
associated with an increased risk of adverse cardiac outcomes.
Concerning echocardiographic measurements, both subpul-
monary ventricular end-diastolic dimension and sRV septal
strain measurements were found to be associated with end
points. This study also conﬁrmed tricuspid regurgitation as a
risk factor for HF. Most blood biomarkers were associated with
adverse cardiac events, of which GDF-15 yielded the strongest
association, even stronger than NT-proBNP. Risk stratiﬁcation
in adults with sRV should therefore focus on clinical variables,
echocardiographic analysis, and blood biomarkers; however,
strain analysis may be less feasible compared with the use of
clinical and blood biomarkers.
Previous Studies
NT-proBNP is the most widely used and studied blood
biomarker for risk stratiﬁcation in the adult congenital heart
disease population18 and is one of the few blood biomarkers
that has previously been investigated in sRV patients.
Westhoff-Bleck et al investigated NT-proBNP in a prospective
cohort study of 116 patients with TGA corrected by the atrial
switch procedure and found that NT-proBNP was an indepen-
dent prognostic factor for adverse cardiac outcomes.
Hemoglobin was also assessed, but showed no signiﬁcant
association.19 Popelova et al also found a strong independent
prognostic value of NT-proBNP in TGA patients after the atrial
switch operation.20 One cross-sectional study showed that
hs-TnT was better in detecting patients with sRV dysfunction
than NT-proBNP.21 Surprisingly, our results showed that NT-
proBNP was not the strongest prognostic factor. To the best
of our knowledge, GDF-15, galectin-3, and RDW have never
been described before in this speciﬁc ACHD population,
although according to our study, these biomarkers may be
better predictors for adverse cardiac events than NT-proBNP.
In a large prospective cohort study including all types of
ACHD patients, higher levels of RDW have been investigated
and were shown to be predictive of adverse cardiac
outcomes.22 This same group also demonstrated a signiﬁcant
association between high-sensitive C-reactive protein and
outcomes in ACHD patients.23
Although some cross-sectional studies have been pub-
lished, only a few studies investigated the prognostic value of
echocardiographic measures. Conventional measures such as
sRV ejection fraction based on magnetic resonance imaging
Log-rank: p=0.70 Log-rank: p=0.75
Figure 1. Heart failure–free survival (primary end point) and arrhythmia-free survival (secondary end point) stratiﬁed according to ccTGA and
M-TGA patients. Red line indicates the event-free survival according to M-TGA patients. Blue line indicates the event-free survival according to
ccTGA patients. ccTGA indicates congenitally corrected transposition of the great arteries; M-TGA, transposition of the great arteries corrected
by the Mustard operation.
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or sRV fractional area change have been linked to clinical
outcome,24,25 with longitudinal strain on magnetic resonance
imaging being the most promising. Tricuspid regurgitation is
also a known risk factor for adverse outcomes in these
patients.26,27 Diller et al showed that in patients with a sRV,
there is an adverse ventricular–ventricular interaction, similar
to tetralogy of Fallot patients.24 This adverse interaction
impedes the subpulmonary left ventricular function in a
number of ways; shared myocardial ﬁbers, dyssynchrony, and
septal shift may all play a role. Another mechanism is
because of backward failure of the sRV, leading to increased
stress on the subpulmonary left ventricle. This was also
present in our study, demonstrated by the association
between left ventricular diameters and clinical events.
Current literature is ambiguous regarding the prognostic
value of strain analysis in sRV patients.24,28,29 In our study,
the prognostic value of strain analysis was limited, though we
did ﬁnd an association between septal longitudinal strain and
death or arrhythmia.
Death and HF
The increased risk of HF in patients with a sRV may arise from
different mechanisms: myocardial ischemia caused by the
single coronary artery that has to supply the right ventricle,
and perioperative damage to the myocardium and the right
ventricle which has to deal with a pressure overload. In M-TGA
patients, bafﬂe stenosis or leakages can occur and are
associated with a worse outcome.7,30,31
Regarding the clinical variables, NYHA class >1 was
associated with death or HF, as well as a lower systolic
blood pressure. Lower systolic blood pressure could be a sign
of subclinical systemic ventricular failure, though mean
systolic blood pressure still was 12514 mm Hg.
The fact that many blood biomarkers were signiﬁcantly
associated with the primary end point may indicate that the
pathophysiology of sRV deterioration is complex and involves
multiple processes and cellular pathways. GDF-15 has been
suggested as a cardiac biomarker by Wollert et al and is
Loss of sinus rhythm
Heart rate
Age
QRS duration
Systolic blood pressure
NYHA class >I
GDF-15
Hs-CRP
RDW
NT-proBNP
Hs-troponin T
Galectin-3
eGFR
Hemoglobin
Clinical variables
Blood biomarkers
Echo biomarkers
Tricuspid regurgitation
LV EDD/BSA
sRV EDD annulus
sRV freewall LS
sRV GCS
sRV septal LS
Death or heart failure
Figure 2. Associations between clinical variables, blood-, and echocardiographic biomarkers, and the primary end point (death or heart failure)
in patients with a systemic right ventricle. Hazard ratios are expressed per increase in standard deviation, except for categorical variables (NYHA
class, loss of sinus rhythm, and tricuspid regurgitation). All blood biomarker levels were log transformed before standardization. sRV GCS and LV
EDD/BSA were only measured in M-TGA patients. Inversed hazard ratios (for comparison purposes); hemoglobin=2.13, eGFR=1.54. BSA
indicates body surface area; CRP, C-reactive protein; EDD, end-diastolic dimension; eGFR, estimated glomerular ﬁltration rate; GDF-15, growth
differentiation factor-15; GCS, global circumferential strain; GLS, global longitudinal strain; LS, longitudinal strain; M-TGA, Mustard transposition
of the great arteries; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association functional class; RDW, red cell
distribution width; sRV, systemic right ventricle.
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identiﬁed as an independent predictor of mortality in many
different populations, such as acute and chronic HF, atrial
ﬁbrillation, coronary artery disease, and in the community-
dwelling elderly.32 It is therefore thought that GDF-15 is
secreted in response to multiple processes, including hypoxia,
inﬂammation, and oxidative stress. In contrast, NT-proBNP is
primarily induced by myocardial stretch, and this might be
only a partial reﬂection of deterioration of sRV function. This
could explain why GDF-15 seems to be even better as
predictor for adverse outcomes than NT-proBNP according to
our data. As proposed by the study of Opotowsky et al,
inﬂammation might play a role in the pathophysiology of
ACHD.23 Our study supports this by the associations found
between hs-CPR and both end points in this study. Mecha-
nisms contributing to hs-TnT secretion in sRV patients might
be a combination of loss of myocardiocytes caused by
increased wall stress and ischemia caused by failing oxygen
supply of the right ventricle by the single coronary artery.
However, as mechanisms of hs-TnT secretion in the case of
chronic HF are still not fully elucidated, secretion of hs-TnT in
sRV is even more speculative.33
Pettersen et al described that the sRV undergoes certain
changes in order to be able to support a high-pressure
circulation: Longitudinal shortening diminishes, while circum-
ferential shortening signiﬁcantly enhances.34 In the present
study, we found no association between strain measurements
and the primary end point. Two recent studies reported absent
associations between sRV systolic function on cardiac
magnetic resonance imaging and exercise capacity and
therefore concluded that the value of sRV imaging at rest
seems to be limited.28,29 We can corroborate these ﬁndings
with this prospective study, though the difﬁculty in analyzing
sRV should also be taken into account.
This study showed that ventricular dilatation measured by
the left ventricular end-diastolic dimension was associated
with death or HF, which can be explained by backward failure
of the sRV resulting in subpulmonary ventricular dilatation. A
similar process is seen in HF patients with anatomically
Loss of sinus rhythm
Heart rate
Age
QRS duration
Systolic blood pressure
NYHA class >I
GDF-15
Hs-CRP
RDW
NT-proBNP
Hs-troponin T
Galectin-3
eGFR
Hemoglobin
Clinical variables
Blood biomarkers
Echo biomarkers
Tricuspid regurgitation
LV EDD/BSA
sRV EDD annulus
sRV freewall LS
sRV GCS
sRV septal LS
Death or arrhythmia
Figure 3. Associations between clinical variables, blood and echocardiographic biomarkers, and the secondary end point (death or
arrhythmia). HRs are expressed per increase in standard deviation, except for categorical variables (NYHA class, loss of sinus rhythm, and
tricuspid regurgitation). All blood biomarker levels were log transformed before standardization. sRV GCS and LV EDD/BSA were only measured
in M-TGA patients. Inversed HRs (for comparison purposes): hemoglobin=1.49, eGFR=1.54. BSA indicates body surface area; CRP, C-reactive
protein; EDD, end-diastolic dimension; eGFR, estimated glomerular ﬁltration rate; GCS, global circumferential strain; GDF-15, growth
differentiation factor-15; GLS, global longitudinal strain; HRs, hazard ratios; Hs-troponin-T, high-sensitive troponin T; LS, longitudinal strain; LV,
left ventricular; M-TGA, Mustard transposition of the great arteries; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart
Association functional class; RDW, red cell distribution width; sRV, systemic right ventricle.
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normal hearts; the deterioration of the contralateral ventricle
is an ominous sign of end-stage HF. Enlarged left ventricular
end-diastolic dimension could also be the result of a residual
shunt or bafﬂe leak. However, patients with severe residual
shunt of bafﬂe would have undergone an intervention, so
therefore it is less likely the enlarged dimensions are the
results of residual shunts or bafﬂe leaks. Nevertheless, former
shunts and leaks may still have contributed to the enlarged
left ventricular dimension.
Another prevalent problem in sRV patients is tricuspid
regurgitation. Although it is still debatable whether tricuspid
regurgitation leads to sRV dysfunction or whether sRV
dysfunction causes tricuspid regurgitation, tricuspid regurgi-
tation has been associated with the risk of HF.26 Our data
support the presence of tricuspid regurgitation as a risk factor
for HF. Notably, tricuspid regurgitation was not associated
with the occurrence of arrhythmias.
Arrhythmias
Similar to the primary end point, NYHA class >1 and lower
systolic blood pressure were signiﬁcantly associated with an
increased risk of the secondary end point. Notably, loss of
sinus rhythm did not have these increased risks. An
explanation for this might be that patients who at baseline
already have a pacemaker rhythm or atrial ﬁbrillation are
excluded from the occurrence of some atrial arrhythmias,
while patients who are still in sinus rhythm at baseline can
lose their sinus rhythm and may therefore be more likely to
experience an event during follow-up.
Studies about the prognostic value of biomarkers in relation
to arrhythmias are limited in these patients, even though they
are characterized by a high burden of arrhythmias.6 This is
conﬁrmed by our study. There are several probable causes for
this, the ﬁrst of which is the congenital defect itself. ccTGA
patients have an abnormal conduction pathway in which the
conduction system takes a longer course to the ventricles.
Secondly, perioperative damage may result in myocardial
ﬁbrosis, which may lead to arrhythmias. Thirdly, myocardial
stretch caused by HF may give rise to arrhythmias.
NT-proBNP was not associated with arrhythmias in our
study, whereas GDF-15 and RDW did show a strong associ-
ation with the occurrence of arrhythmias. An explanation may
be that arrhythmias do not originate solely from myocardial
stretch or hypertrophy but may be caused by a combination of
myocardial ﬁbrosis, inﬂammation, hypoxia, and myocardial
stress.30 GDF-15 has been associated with cardiac ﬁbrosis in
nonischemic cardiomyopathy35 and RDW has been suggested
as being “an overall cardiovascular barometer” because of its
probable reﬂection of diverse pathophysiological processes.36
This might explain the strong prognostic value found for both
biomarkers for arrhythmias.
Aggregating the data from our study, and taking into
consideration the lack of strong associations between
echocardiography and blood biomarkers and the predictive
ability of blood biomarkers in particular, it is likely that blood
biomarkers are secreted in an earlier onset of subclinical
deterioration in sRV patients, while echocardiographic
changes may be revealed in a later disease stage and are
therefore less predictive of cardiac events. The fact that most
blood biomarkers were associated with the end points even
after adjustment for NYHA class strengthens the idea that
blood biomarkers reﬂect subclinical sRV failure.
Clinical Implications
A wide range of blood biomarkers yielded prognostic value in
this study. Besides NT-proBNP, other biomarkers play a
pivotal role, and GDF-15 speciﬁcally can be a potential
biomarker for risk stratiﬁcation. Some disadvantages of blood
biomarkers are the high laboratory costs and the sometimes
restricted availability. GDF-15 is a relative expensive biomar-
ker and often not available in standard laboratories. On the
other hand, RDW also showed strong prognostic value and
furthermore this biomarker is widely available, low cost, and
incorporated in a standard complete blood count.
For daily clinical practice, ﬁndings such as an abnormal
NYHA class and lower blood pressures can indicate high-risk
patients, and these patients should probably be followed up
more closely.
While echocardiography plays a key role in the follow-up of
patients with complex ACHD, high-quality image acquisition
requires skilled sonographers, is hampered by complex
anatomy and orientation in the thorax, and is highly user-
dependent, which may limit its prognostic value. Newer
echocardiography techniques such as strain analysis seem to
have little prognostic value in sRV patients and their role in
clinical practice is currently unclear. Nevertheless, more
easily obtainable conventional echocardiographic measure-
ments such as subpulmonary end-diastolic dimension can still
be valuable measures for risk stratiﬁcation in daily clinical
practice.
Limitations
This study is limited by the relatively small sample size, and
conclusions drawn from this study should therefore be treated
with caution. We did not observe differences in event-free
survival in ccTGA and M-TGA patients; however, underlying
mechanisms of HF and arrhythmias may be different in these
patients, and therefore prognostic biomarkers and echocar-
diographic measurements could behave differently in each
diagnosis subgroup. Unfortunately, the low sample size
allowed us to only perform subgroup analysis in M-TGA
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patients. Also, this study lacked statistical power to adjust for
multiple potential confounders and biomarkers in multivari-
able analysis. Because we used composite end points, it
should be taken into account that associations could be
driven more by 1 of the speciﬁc components.
We also did not take into account the concomitant
congenital heart defects in both TGA groups, which can
inﬂuence the prognosis. We acknowledge the considerable
limitation concerning the limited sample size of this study, yet
to the best of our knowledge this is the largest study that
provided prospective longitudinal data including a wide range
of biomarkers and echocardiographic strain analysis in
patients with a sRV.
Conclusions
High event rates in adults with a sRV demand adequate risk
stratiﬁcation. Assessing clinical characteristics and blood
biomarkers as well as conventional echocardiographic mea-
surements seems most expedient for adequate risk assess-
ment in these patients. However, the contribution of novel
echocardiographic strain measurements seems to be limited
in this perspective. This study suggests that the underlying
pathophysiology of ventricular deterioration in patients with a
sRV is complex, requiring a comprehensive clinical approach.
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Standard 
deviation 
Clinical variables 
 Age, years 9 
 Heart rate, beats/min 13 
 Systolic blood pressure, mmHg 14 
 QRS duration, ms 21 
Blood biomarkers (log)↓* 
  NT-proBNP, pmol/L 1.34 
  Hs-troponin-T, ng/L 1.39 
  GDF-15, ng/L 0.77 
  Hs-CRP, mg/L 1.57 
  Galectin-3, ng/mL 0.39 
  RDW, % 0.11 
  eGFR, mL/min/1.73m2 0.17 
  Hemoglobin, mmolFe/L 0.15 
Echocardiographic markers 
sRV dimensions 
   sRV end-diastolic annulus,  mm/m2 8.6 
 Strain parameters 
    LS of the sRV free wall, % 4.0 
    LS of the sRV septal wall, % 3.3 
    GCS of the sRV, % 3.8 
LV dimensions 
    LV end-diastolic diameter, mm/m2 4.0 
*Blood biomarkers were log transformed before standardization and therefore the SD’s reported belong 
to the log transformed blood biomarker levels.  CRP= C-reactive protein, eGFR= estimated glomerular 
filtration rate, GDF-15= growth differentiation factor-15, GCS= global circumferential strain, Hs= high 
sensitive, LS= longitudinal strain, LV= left ventricular, NT-proBNP= N-terminal pro b-type natriuretic 
peptide, RDW= red cell distribution width, sRV= systemic right ventr
Table S1. Standard deviations of variables included in univariable Cox regression, for interpretative purposes 
of standardized hazard ratios.  
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*Hazard ratios are expressed per increase in standard deviation  for continuous variables. † In adult 
patients with transposition of the great arteries operated by the Mustard procedure only. ‡ Not enough 
power to perform multivariable analysis.  CRP= C-reactive protein, eGFR= estimated glomerular 
filtration rate, GDF-15= growth differentiation factor-15, GCS= global circumferential strain, GLS= 
global longitudinal strain, Hs= high sensitive, LS= longitudinal strain, LV= left ventricular, NT-
proBNP= N-terminal pro b-type natriuretic peptide, NYHA= New York Heart Association, RDW= red 
cell distribution width, sRV= systemic right ventricle 
Analysis with adjustment for NYHA functional class 
Primary endpoint Secondary endpoint 
 
HR* 95%CI p-value HR* 95%CI p-value
Clinical characteristics 
 Age 1.04 0.38-1.58 0.86 0.95 0.66-1.37 0.80
 Heart rate 1.47 0.89-2.44 0.14 1.48 1.02-2.13 0.038
 Systolic blood pressure 0.65 0.39-1.09 0.10 0.55 0.35-0.87 0.009
 QRS duration 1.23 0.80-1.91 0.35 1.30 0.92-1.83 0.13
 Loss of sinus rhythm  2.16 0.85-5.56 0.11 1.61 0.75-3.47 0.23
Blood biomarkers 
  NT-proBNP 1.79 1.15-2.80 0.010 1.08 0.73-1.61 0.70
  Hs-troponin-T 1.70 1.03-2.78 0.036 1.40 0.96-2.03 0.08
  GDF-15 2.24 1.49-3.35 <0.001 1.86 1.35-2.56 <0.001 
  Hs-CRP 2.02 1.18-3.44 0.010 1.38 0.92-2.06 0.12 
  Galectin-3 1.30 0.80-2.11 0.29 1.45 0.98-2.14 0.06 
  RDW 1.91 1.38-2.65 <0.001 1.71 1.26-2.31 0.001 
  eGFR 0.73 0.52-1.03 0.07 0.72 0.53-0.97 0.032 
  Hemoglobin 0.52 0.36-0.73 <0.001 0.72 0.53-1.00 0.047 
Echocardiographic markers 
Tricuspid regurgitation 1.74 1.11-2.74 0.016 1.23 0.85-1.79 0.28 
sRV dimensions 
   sRV end-diastolic annulus 1.66 0.97-2.86 0.07 0.94 0.62-1.40 0.74 
 Strain parameters 
      LS of the sRV free wall 1.19 0.73-1.94 0.50 1.06 0.71-1.58 0.74 
      LS of the sRV septal wall 0.87 0.54-1.41 0.58 0.65 0.43-0.98 0.039 
      GCS of the sRV† -‡ - - 0.64 0.42-0.98 0.038 
LV dimensions 
   LV end-diastolic diameter† -‡ - - 1.41 0.98-2.04 0.07 
Table S2. Associations between clinical variables, blood- and echocardiographic markers and the primary- 
(death or heart failure) and secondary endpoint (death or arrhythmia), with adjustment for New York Heart 
Association functional class in adults with a systemic right ventricle. 
D
ow
nloaded from
 http://ahajournals.org by on November 27, 2019
*Hazard ratios expressed per increase in standard deviation  for continuous variables. #Indexed for body 
surface area.  CRP= C-reactive protein, eGFR= estimated glomerular filtration rate, GDF-15= growth 
differentiation factor-15, GCS= global circumferential strain, Hs= high sensitive, LS= longitudinal 
strain, LV= left ventricular, NT-proBNP= N-terminal pro b-type natriuretic peptide, NYHA= New York 
Heart Association, RDW= red cell distribution width, sRV= systemic right ventricle 
Mustard TGA patients (n=64) 
Primary endpoint 
(n=15) 
Secondary endpoint 
(n=22) 
 
HR* 95%CI p-value HR* 95%CI p-value
Clinical variables 
 Age 2.54 1.32-4.90 0.005 2.70 1.48-4.93 0.001
 Heart rate 1.48 0.87-2.52 0.15 1.53 1.03-2.28 0.036
 Systolic blood pressure 0.53 0.30-0.93 0.027 0.46 0.27-0.79 0.005
 NYHA >1  5.25 1.89-14.53 0.001 3.87 1.62-9.27 0.002
 QRS duration 1.53 0.97-2.42 0.07 1.50 1.02-2.20 0.042
 Loss of sinus rhythm  3.53 1.28-9.80 0.015 2.75 1.15-6.62 0.023
Blood biomarkers 
  NT-proBNP 2.85 1.75-4.64 <0.001 1.87 1.24-2.83 0.003
  Hs-troponin-T 2.58 1.55-4.31 <0.001 2.10 1.40-3.32 <0.001 
  GDF-15 2.47 1.61-3.78 <0.001 2.81 1.92-4.12 <0.001 
  Hs-CRP 2.31 1.31-4.07 0.004 1.74 1.13-2.68 0.012 
  Galectin-3 2.27 1.31-3.93 0.003 2.50 1.51-4.14 <0.001 
  RDW 2.07 1.48-2.89 <0.001 2.53 1.64-4.04 <0.001 
  eGFR 0.60 0.44-0.83 0.002 0.52 0.37-0.74 <0.001 
  Hemoglobin 0.49 0.34-0.72 <0.001 0.65 0.44-0.96 0.030 
Echocardiographic markers 
Tricuspid regurgitation 1.60 0.96-2.68 0.074 1.23 0.78-1.95 0.38 
sRV dimensions 
   sRV end-diastolic annulus 2.00 0.99-4.05 0.05 1.25 0.68-2.31 0.47 
 Strain parameters 
    LS of the sRV free wall 0.62 0.32-1.19 0.15 0.71 0.42-1.20 0.20 
    LS of the sRV septal wall 0.73 0.44-1.22 0.23 0.62 0.39-0.98 0.039 
    GCS of the sRV 0.77 0.46-1.30 0.33 0.69 0.46-1.05 0.09 
LV dimensions 
    LV end-diastolic diameter# 1.95 1.34-2.85 0.001 1.70 1.21-2.38 0.002 
Table S3. Associations between clinical variables, blood- and echocardiographic markers and the primary and 
secondary endpoint, restricted to adult patients with transposition of the great arteries operated by the 
Mustard procedure.  
D
ow
nloaded from
 http://ahajournals.org by on November 27, 2019
  
 
 
ASD= atrial septal defect, VSD= ventricular septal defect, ACHD= adult congenital heart disease, TGA= 
transposition of the great arteries 
2533 unique patients with at least one visit to 
the outpatient clinic of the adult congenital 
cardiology between April 5th 2011 and April 
16th  2013 
602 ACHD patients enrolled in initial cohort 
study 
267 patients not approached due to missing 
echocardiogram  
1664 patients not enrolled because of: age <18 years, 
pregnancy, mild cardiac lesion (isolated ASD or 
VSD), not capable of understanding and signing 
informed consent, denial to participate in study 
(<5% of patients), no routine visit, random logistical 
reasons 
86 patients with a systemic right ventricle due to 
a transposition of the great arteries (TGA); 
• 65 Mustard TGA patients
• 21 congenitally corrected TGA patients
516 patients with another congenital heart diagnosis 
than a systemic right ventricle due to TGA 
Figure S1. Flowchart of the patient selection process of the prospective observational cohort study consisting of 
adults with a systemic right ventricle.  
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